ScholarIQanswers from OpenAlex
European Heart Journal - Cardiovascular Pharmacotherapy
JournalCitation impact & published research
European Heart Journal - Cardiovascular Pharmacotherapy is a journal indexed in ScholarIQ from OpenAlex.
How many works does European Heart Journal - Cardiovascular Pharmacotherapy have?
ScholarIQindexed works
European Heart Journal - Cardiovascular Pharmacotherapy has 963 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does European Heart Journal - Cardiovascular Pharmacotherapy have?
ScholarIQcitation count
European Heart Journal - Cardiovascular Pharmacotherapy has 16,096 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of European Heart Journal - Cardiovascular Pharmacotherapy?
ScholarIQh-index
European Heart Journal - Cardiovascular Pharmacotherapy has an h-index of 59 in OpenAlex.
What is the article processing charge of European Heart Journal - Cardiovascular Pharmacotherapy?
ScholarIQarticle processing charge
European Heart Journal - Cardiovascular Pharmacotherapy lists an article processing charge of 3,895 USD in OpenAlex.
What is the OpenAlex record for European Heart Journal - Cardiovascular Pharmacotherapy?
ScholarIQopenalex
The OpenAlex for European Heart Journal - Cardiovascular Pharmacotherapy is on the source record.
What are the most-cited papers on European Heart Journal - Cardiovascular Pharmacotherapy?
ScholarIQmost cited works
Efficacy and Safety of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER trial): a multicentre, randomized, double-blind, placebo-controlled trial
Masanori Asakura, Shin Ito, Takahisa Yamada, Yoshihiko Saito, Kazuo Kimura, Akira Yamashina, Atsushi Hirayama, Youichi Kobayashi, Akihisa Hanatani, Mitsuru Tsujimoto, Satoshi Yasuda, Yukio Abe, Yorihiko Higashino, Yodo Tamaki, Hiroshi Sugino, Hiroyuki Niinuma, Yoshitaka Okuhara, Toshimi Koitabashi, Shin‐ichi Momomura, Kuniya Asai, Akihiro Nomura, Hiroya Kawai, Yasuhiro Satoh, Tsutomu Yoshikawa, Ken–ichi Hirata, Yoshiaki Yokoi, Jun Tanaka, Yoshisato Shibata, Yasuhiro Maejima, Shunsuke Tamaki, Hiroyuki Kawata, Noriaki Iwahashi, Masatake Kobayashi, Yoshiharu Higuchi, Akiko Kada, Haruko Yamamoto, Masafumi Kitakaze
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis
Gerasimos Filippatos, Stefan D. Anker, Phyllis August, Andrew J.S. Coats, James L. Januzzi, Boris Mankovsky, Peter Rossing, Luís M. Ruilope, Bertram Pitt, Pantelis Sarafidis, John R. Teerlink, Chris J. Kapelios, Martin Gebel, Meike Brinker, Amer Joseph, Andrea Lage, George L. Bakris, Rajiv Agarwal
Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease
Craig I Coleman, William L. Baker, Anna‐Katharina Meinecke, Daniel Eriksson, Brandon Martinez, Thomas J. Bunz, Mark J. Alberts
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease
Gerasimos Filippatos, Stefan D. Anker, Bertram Pitt, Darren K. McGuire, Peter Rossing, Luís M. Ruilope, Javed Butler, Ewa A. Jankowska, Erin D. Michos, Dimitrios Farmakis, Alfredo E. Farjat, Peter Kolkhof, Andrea Scalise, Amer Joseph, George L. Bakris, Rajiv Agarwal
Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF
Mingming Yang, Alasdair D Henderson, Inder S. Anand, Akshay S. Desai, Carolyn S.P. Lam, Aldo P. Maggioni, Felipe A. Martínez, Jean L. Rouleau, Karl Swedberg, Muthiah Vaduganathan, Dirk J van Veldhuisen, Faı̈ez Zannad, Michael R. Zile, Milton Packer, Adel R. Rizkala, Eldrin F. Lewis, Pardeep S. Jhund, Scott D. Solomon, John J.V. McMurray